Ann: Appendix 3B - Star Bright Placement Issue, page-24

Call me silly but if a credible plan is outlined I will be buying a few more when they come out of halt.  Considering the market cap, there is so much latent potential in adapt and tavr.  We always knew adapt would be a hard slog as lemataire vascular clearly showed us they had years n years of cash burn but they (owners and shareholders) are reaping big rewards now.  Same business model and blueprint.  Still adamant that despite the setback in forecasts and, say cashflow positive is still 12 months away, the company is still closer to being cash flow positive than 99% of other Aussie biotechs on the ASX...